Mirum Pharmaceuticals Q2 2024 GAAP EPS $(0.52) Misses $(0.47) Estimate, Sales $77.875M Beat $75.246M Estimate
Portfolio Pulse from Benzinga Newsdesk
Mirum Pharmaceuticals (NASDAQ:MIRM) reported Q2 2024 GAAP EPS of $(0.52), missing the $(0.47) estimate, but achieved sales of $77.875M, beating the $75.246M estimate. Sales increased by 107.68% year-over-year.
August 07, 2024 | 8:20 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Mirum Pharmaceuticals reported a Q2 2024 GAAP EPS of $(0.52), missing the $(0.47) estimate, but achieved sales of $77.875M, beating the $75.246M estimate. Sales increased by 107.68% year-over-year.
The mixed earnings report, with a miss on EPS but a beat on sales, suggests a neutral short-term impact on the stock price. The significant year-over-year sales growth is a positive indicator, but the EPS miss may offset this.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100